In acute myeloid leukemia (AML), CEBPA is found mutated in approximately 10% of cases, and studies in mouse have shown that the tumor-suppressive functions of C/EBPα can be ascribed to its ability to balance the proliferation and differentiation of hematopoietic stem and progenitor cells (HSPCs) populations [18], [22]. This evidence concerns the gene CEBPA and acute myeloid leukemia.